109 results about "Muscle disease" patented technology

The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and / or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.

The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and / or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and / or suppress the rate of formation of reactive products and toxic compounds.

The invention aims at providing a muscle disease monitoring method based on multi-channel surface electromyography (sEMG). The method comprises the steps that preprocessing is conducted on multi-channel sEMG signals firstly, a first channel is selected as a reference, and differencing is conducted on the signals of other channels and the signal of the first channel; then distribution moments are extracted through a K-means clustering convolution kernel compensation (KMCKC) method, and a single waveform is extracted; finally, multiple features of the waveform are fused, and the muscle state is evaluated. Due to the fact that external interference has influence on all electrodes, by meas of differencing between the signal of the first channel and the sEMG signals of original multiple channels, the external interference is effectively reduced, subsequent detection results cannot be affected, and the accuracy of muscle detection is improved. By means of application of the multi-feature parameters, the instability of single-parameter monitoring is effectively avoided, and the monitoring robustness is promoted. By means of the muscle disease monitoring method based on the multi-channel surface electromyography (sEMG), the defects in the prior art are effectively overcome, and important application value is achieved.

This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and / or diseases or disorders of bone and muscle.

The present invention describes a transgenic mouse susceptible to neuromuscular disease. The present invention also includes methods for treatment of neuromuscular diseases by interfering with activity between androgen and androgen receptors exclusively in the muscle fibers.

The present invention relates to a composition for preventing or treating muscle diseases or improving muscular function, containing fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract. According to the present invention, fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract increases the protein expression of p-mTOR, which is a main gene involved in muscle protein synthesis, inhibits the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation, and increases the mRNA expression of MyoD and myogenin involved in muscle differentiation, thereby having an effect of remarkably increasing muscular function. In addition, since the composition of the present invention is a natural product, the composition can be safely used without side effects, thereby being usable in medicine, food, cosmetic products, livestock feed, a feed additive and the like.

The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.

The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or avariant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAsare over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention ofan Atrogin-1 - dependent muscular disease and cachexia.